Shifts in Lipid-Lowering Treatment Approaches for Acute Coronary Syndromes Following New Insurance Policies in China: An Analysis Based on Real-World Data - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Shifts in Lipid-Lowering Treatment Approaches for Acute Coronary Syndromes Following New Insurance Policies in China: An Analysis Based on Real-World Data
Clinical Scorecard: Shifts in Lipid-Lowering Treatment Approaches for Acute Coronary Syndromes Following New Insurance Policies in China: An Analysis Based on Real-World Data
At a Glance
Category
Detail
Condition
Acute Coronary Syndromes (ACS)
Key Mechanisms
Reduction of low-density lipoprotein cholesterol (LDL-C) via lipid-lowering therapies (statins, ezetimibe, PCSK9 inhibitors) to reduce atherosclerotic cardiovascular disease risk
Target Population
Chinese patients aged 18–80 years diagnosed with STEMI, NSTEMI, or unstable angina
Care Setting
Hospital and post-discharge follow-up in chest pain centers across China
Key Highlights
New national healthcare insurance policy in China from January 2022 reduced cost of PCSK9 inhibitors, potentially increasing their use in ACS management.
Real-world data from 4441 chest pain centers in China were analyzed to assess lipid-lowering treatment patterns before and after insurance policy change.
LDL-C target attainment rates and use of intensive lipid-lowering therapies remain suboptimal despite guideline recommendations.
Guideline-Based Recommendations
Diagnosis
Diagnosis of ACS based on symptoms, electrocardiographic evidence, and cardiac troponin levels by cardiologists according to standard guidelines.
Management
Use of intensive lipid-lowering therapy including high-intensity statins, ezetimibe, and PCSK9 inhibitors to achieve LDL-C targets.
LDL-C targets: <1.4 mmol/L with >50% reduction for extremely high-risk patients; <1.8 mmol/L with >50% reduction for others.
Monitoring & Follow-up
Lipid profiles (TC, TG, LDL-C, HDL-C) measured at admission, discharge, 1-month, and 3-month follow-ups to assess LDL-C goal attainment.
Risks
Underuse of non-statin lipid-lowering therapies and failure to achieve LDL-C targets increase risk of recurrent ASCVD events.
Patient & Prescribing Data
Patients with ACS aged 18–80 years in China receiving lipid-lowering therapies post-discharge.
Following insurance coverage of PCSK9 inhibitors, usage patterns of lipid-lowering therapies including statins, ezetimibe, and PCSK9 inhibitors were tracked at discharge and follow-ups to evaluate changes in treatment intensity and LDL-C control.
Clinical Best Practices
Implement guideline-recommended intensive lipid-lowering therapy promptly after ACS diagnosis.
Utilize insurance coverage policies to improve access to PCSK9 inhibitors for very high-risk patients.
Regularly monitor lipid profiles post-discharge to ensure LDL-C targets are met and adjust therapy accordingly.
Investigators found that adding pregnancy-related and female-specific factors modestly improved postpartum cardiovascular risk prediction compared with traditional risk factors alone.
A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness
